GeoVax Labs, Inc. (GOVX) SEC filings

GOVXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30

$1.71−0.33 (-16.42%)

Close on Nov 13, 2026Market cap $717.73KP/E –Yield –

SEC filings

40 of GeoVax Labs's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Sep 30, 2026	Nov 12, 2026	SEC EDGAR
Current report	8-K	Nov 10, 2026	Nov 12, 2026	SEC EDGAR
Current report	8-K	Nov 5, 2026	Nov 9, 2026	SEC EDGAR
Current report	8-K	Nov 5, 2026	Nov 6, 2026	SEC EDGAR
Current report	8-K	Oct 27, 2026	Oct 27, 2026	SEC EDGAR
Current report	8-K	Oct 23, 2026	Oct 27, 2026	SEC EDGAR
Proxy statement	DEF 14A	Oct 27, 2026	Sep 10, 2026	SEC EDGAR
Current report	8-K	Sep 10, 2026	Sep 10, 2026	SEC EDGAR
Current report	8-K	Aug 27, 2026	Aug 28, 2026	SEC EDGAR
Current report	8-K	Aug 25, 2026	Aug 28, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Jul 27, 2026	SEC EDGAR
Current report	8-K	Jul 27, 2026	Jul 27, 2026	SEC EDGAR
Current report	8-K	Jul 7, 2026	Jul 10, 2026	SEC EDGAR
Current report	8-K	Jun 17, 2026	Jun 17, 2026	SEC EDGAR
Current report	8-K	May 18, 2026	May 19, 2026	SEC EDGAR
Current report	8-K	May 14, 2026	May 14, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 14, 2026	SEC EDGAR
Current report	8-K	May 7, 2026	May 7, 2026	SEC EDGAR
Proxy statement	DEF 14A	Jun 17, 2026	Apr 27, 2026	SEC EDGAR
Current report	8-K	Apr 15, 2026	Apr 15, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Apr 15, 2026	SEC EDGAR
Current report	8-K	Mar 31, 2026	Mar 31, 2026	SEC EDGAR
Current report	8-K	Feb 13, 2026	Feb 17, 2026	SEC EDGAR
Current report	8-K	Jan 9, 2026	Jan 12, 2026	SEC EDGAR
Current report	8-K	Dec 19, 2025	Dec 22, 2025	SEC EDGAR
Current report	8-K	Nov 26, 2025	Nov 26, 2025	SEC EDGAR
Current report	8-K	Nov 13, 2025	Nov 13, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 13, 2025	SEC EDGAR
Proxy statement	DEF 14A	Nov 26, 2025	Oct 14, 2025	SEC EDGAR
Current report	8-K	Sep 30, 2025	Sep 30, 2025	SEC EDGAR
Current report	8-K	Jul 31, 2025	Aug 1, 2025	SEC EDGAR
Current report	8-K	Jul 28, 2025	Jul 29, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Jul 28, 2025	SEC EDGAR
Current report	8-K	Jul 1, 2025	Jul 2, 2025	SEC EDGAR
Current report	8-K	Jun 5, 2025	Jun 5, 2025	SEC EDGAR
Current report	8-K	May 1, 2025	May 1, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 1, 2025	SEC EDGAR
Current report	8-K	Apr 11, 2025	Apr 14, 2025	SEC EDGAR
Proxy statement	DEF 14A	Jun 5, 2025	Apr 14, 2025	SEC EDGAR
Current report	8-K	Mar 27, 2025	Mar 28, 2025	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in GeoVax Labs's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-25 reverse split on Jan 12, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is GOVX.

Compare: GOVX vs VCNX · GOVX vs RNAC · GOVX vs NWBO · GOVX vs PVCT · GOVX vs MNOV

Revenue growth-100.0% · median 105.1%

Company	Revenue	Growth
NWBO	$2.86M	+204.8%
RNAC	$1.03M	–
MNOV	$935.72K	–
VCNX	$601.00K	+5.4%
GOVX	$0	-100.0%
PVCT	–	–

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 19
Held by institutions: 6.7%
Auditor: WIPFLI LLP
SEC CIK: 832489

Advertisement
300 × 250

See a number that looks wrong?